Endeavor drug-eluting stent approved
This article was originally published in The Gray Sheet
Executive Summary
Medtronic launches its Endeavor zotarolimus-eluting stent immediately upon FDA approval Feb. 1, and expects to ship 100,000 units to U.S. hospitals in the next 30 days. Endeavor is the first drug-eluting stent approved in nearly four years and the third DES on the U.S. market. Device industry analysts expect Endeavor to take 15%-20% of the near $2 billion U.S. DES market. As conditions of approval, Medtronic will conduct a 2,000-patient U.S. post-approval study, to be combined with data from 3,300 patients outside the U.S., as well as continue to follow patients in six Endeavor trials for five years. Abbott's Xience everolimus-eluting stent, also up for FDA approval this year, got a positive recommendation from an FDA advisory committee in November (1"The Gray Sheet" Dec. 3, 2007, p. 3)
You may also be interested in...
FDA: Review Of International Trial Design Can Facilitate U.S. Approval
FDA is more likely to let companies use international trial data in a U.S. marketing application if they ask regulators here to review the study protocols first
Endeavor Stent’s Debut Drives 22% Growth In Medtronic Cardiovascular Biz
Medtronic's Endeavor zotarolimus-eluting coronary stent captured over 20% of the U.S. drug-eluting stent market by the tail end of the firm's fiscal fourth quarter (ended April 25), the company reported May 20
Canada approves Endeavor
Health Canada's Therapeutic Products Directorate approves Medtronic's Endeavor zotarolimus-eluting coronary stent, the firm announces March 26. The approval was based on seven studies with a total of 4,100 patients followed up to four years. As a condition of approval, the company will submit to Health Canada annual updates on its 5,000-patient post-market trial, as well as other studies investigating the risk of stent thrombosis, myocardial infarction and optimal dual anti-platelet therapy. Medtronic launched Endeavor in Europe in 2005 and began U.S. marketing Feb. 1 following FDA approval (1"The Gray Sheet" Feb. 4, 2008, In Brief)